post-transplant lymphoproliferative disorder

(redirected from Post-transplant lymphoproliferative disease)
Also found in: Acronyms.

post-transplant lymphoproliferative disorder

A family of Epstein-Barr virus-associated lymphoid expansions with a range of histologies, from infectious mononucleosis-like lymphoid hyperplasia to monoclonal neoplasms, that may not be classifiable as specific types of non-Hodgkin lymphoma, even if typical genetic defects are present. Monoclonal post-transplant lymphoproliferative disorders (PTLDs) do not regress when immunosuppression is withdrawn. PTLD occurs in 1–10% of organ transplant recipients; most cases that occur in solid organ recipients are of host origin.

Diagnosis
Post-transplant patients at risk for PTLD can be identified by detecting expression (as small mRNA) of the EBER-1 gene.

Note
Malignant features may regress with reduced immunosuppression.
References in periodicals archive ?
Studies of Epstein-Barr virus (EBV) infection and immune response, culminating with a Phase I trial of a cellular immunotherapy for the prevention and treatment of post-transplant lymphoproliferative disease (PTLD).
In addition to the lung function study, other results from the aerosol cyclosporine trial to be presented at the ISHLT meeting found that patients who developed post-transplant lymphoproliferative disease (PTLD), a complication from immunosuppression involving tumor growth that is often fatal, fared much better if they were being treated with the spray.

Full browser ?